Abstract: Provided herein are gene editing systems and/or compositions comprising RNA guides targeting HAO1 for use in genetic editing of the HAO1 gene. Also provide herein are methods of using the gene editing system for introducing edits to the HAO1 gene and/or for treatment of primary hyperoxaluria (PH), and processes for characterizing the gene editing system.

Abstract: A process for evaluating efficacy of a deodorant product includes: introducing sweat into a main channel formed in a fluidic device satisfying particular requirements; measuring a flow rate of the sweat in the main channel and transmitting the flow rate to a controller; imposing a pressure set point on the pressure actuator by closed-loop control so the flow rate of the sweat in the main channel is controllable; contacting the sweat and a deodorant product and reacting the sweat and the deodorant product with each other, the deodorant product being provided in a particular manner, wherein while the sweat and the deodorant product react with each other, the flow rate of the sweat in the main channel is maintained at substantially zero; and determining at least one of a physicochemical parameter and a biological parameter of a product of the reaction between the sweat and a the deodorant product.

Abstract: Provided herein are systems, compositions, and methods of introducing protective and/or loss-of-function variants of CCR5 and CCR2. Variants may be introduced using a CRISPR/Cas9-based nucleobase editor or other guide nucleotide sequence-programmable DNA binding protein domain-based fusion protein described herein. Further provided herein are compositions and methods of preventing and treating conditions related to HIV infection and progression as well as to AIDS.

Abstract: This disclosure provides a preserving composition comprising a cholesterol: carrier complex, optionally a cholesterol:cyclodextrin complex (CC complex) and/or a cell permeable antioxidant peptide and a biological buffer and optionally a cryprotectant, wherein the preserving composition is optionally substantially free of animal phospholipid, animal protein and/or animal lipoprotein. The disclosure also provides methods for the use of the preserving composition in cryopreservation of semen or sperm cells. Also provided is a kit comprising the preserving composition having a CC complex, a biological buffer, a cryoprotectant, a carbohydrate, a pH stabilizer, an antibiotic or antibiotic cocktail and/or a cell permeable anti-oxidant peptide.

Abstract: Periosteum harvesting and processing systems and methods enable rapid, efficient, and repeatable harvesting of periosteum tissue from human long bones and processing of the tissue into individual fibers for use in strengthening surgical allograft products. One harvesting and processing method involves providing a human long bone, securing the long bone between two rotating live centers, scraping, using one of a plurality of harvesting tools selected from a harvesting and processing kit, periosteum tissue from the long bone, executing a first wash cycle comprising a hydrogen peroxide wash, executing a second wash cycle comprising an isopropyl alcohol wash, executing a third wash cycle comprising a phosphate buffered saline wash, compressing the periosteum tissue to remove excess fluid, cryofracturing the tissue until a desired fiber size is achieved, and separating the periosteum tissue into individual periosteum fibers having the desired fiber size. Other embodiments are also disclosed.

Abstract: Described herein are methods and compositions for improving plant growth and other properties. The methods and compositions utilize bacteria and bacterial exudates incorporated into plant seeds for improvement of plant growth and other properties.

Abstract: A triple syringe system that allows for a larger combined output of PRP (platelet rich plasma) and PPP (platelet poor plasma). The multi-syringe system allows for the connection of two or more additional syringes. The fractions may be extracted with the multi-syringe system of the present invention at different sequential times, or at the same time.

Abstract: Provided are methods, systems, and kits for cell processing, e.g., for therapeutic use, such as for adoptive cell therapy. The provided methods include transduction methods, in which cells and virus are incubated under conditions that result in transduction of the cells with a viral vector. The incubation in some embodiments is carried out in an internal cavity of a generally rigid centrifugal chamber, such as a cylindrical chamber made of hard plastic, the cavity of which may have a variable volume. The methods include other processing steps, including those carried out in such a chamber, including washing, selection, isolation, culture, and formulation. In particular, the disclosure relates to method providing advantages over available processing methods, such as available methods for large-scale processing. Such advantages include, for example, reduced cost, streamlining, increased efficacy, increased safety, and increased reproducibility among different subjects and conditions.

Abstract: A method is disclosed for coating and patterning hydrogels in order to modify surface properties. The method exploits the water content of the hydrogel and the hydrophobicity of the reaction solvent to create a thin oxide adhesion layer on the hydrogel surface. This oxide adhesion layer enables rapid transformation of the hydrophilic, cell non-adhesive hydrogel into either a highly hydrophobic or a cell-adhesive hydrogel by reaction with an alkylphosphonic acid or an ?,?-diphosphonoalkane, respectively. Also disclosed are coated, patterned hydrogels and constructs comprising the coated, patterned hydrogels.

Abstract: The invention relates to cell-free compositions obtained by culturing adult-derived human liver stem/progenitor cells (ADHLSC) in cell culture medium and isolating the resulting conditioned medium (ADHLSC-CM) that has advantageous properties, such as anti-fibrotic effects. ADHLSC-CM, compositions based on ADHLSC-CM, and other related and derived products, can be used in cell culture processes or as a medicament, more particularly for the treatment of diseases involving organ injury, organ failure, in organ or cell transplantation or the pathological disruption, inflammation, degeneration, and/or proliferation of cells within a tissue or an organ, in particular within liver.

Abstract: Disclosed herein is a method for cultivating primary human pulmonary alveolar epithelial cells (HPAEpiC), which includes cultivating the primary HPAEpiC in a first medium containing a basal medium, a culture supplement, and a Rho kinase inhibitor, and a second medium containing the basal medium and the culture supplement in sequence. The culture supplement includes Jagged-1 (JAG-1) peptide, human Noggin protein, transforming growth factor-? (TGF-?) type I receptor inhibitor SB431542, human fibroblast growth factor 7 (hFGF-7), hFGF-10, and glycogen synthase kinase 3 (GSK-3) inhibitor CHIR99021. Also disclosed is a method for preparing a three-dimensional cell culture of alveolar epithelium using the first medium and the second medium.

Abstract: The invention provides methods for the production of recombinant adeno-associated virus vectors (rAAV), comprising culturing producer cells in media with increased osmolality. Also provided are methods for decreasing the production of helper virus by a rAAV producer cell, comprising culturing the producer cell in media with increased osmolality.

Abstract: Provided are a cell strain HEK293.CS for reducing the production of a replication competent adenovirus, and a construction method and the use thereof. HEK293.CS is a safe adenovirus-producing cell line constructed by knocking out a gene fragment homologous to the Ad5 adenovirus E1 gene in HEK293 and providing a template plasmid to replace said gene fragment with a non-homologous sequence that stabilizes the expression of the E1 gene. Compared with the unmodified HEK293 cell strain, HEK293.CS shows no decrease in growth ability and virus production ability, but does not produce a detectable RCA. HEK293.CS can be used for the mass culture of a recombinant human type 5 adenovirus, and reducing the probability of RCA production in the manufacture process of drugs such as vaccines and antibodies.

Abstract: The present invention relates, in part, to blood-brain barrier-like tissues that comprise engineered E40RF1+ endothelial cells, and to various compositions and methods useful for making and using such blood-brain barrier-like tissues—both in vitro and in vivo.

Abstract: A thread collecting method for easily and simply collecting a bagworm-derived pure silk thread from a bagworm with a small number of processes and a thread collecting device for implementing the thread collecting method are developed and provided. A device that collects a silk thread from a bagworm is provided, the device including: a container that accommodates the bagworm; and an in-and-out hole through which the bagworm is put in and taken out of the container. A width of a maximum short axis cross section of an inner space of the container is in a range from 1.2 times or more to less than 3.1 times relative to a maximum body width of the bagworm being accommodated.

Abstract: The present invention relates to providing artificial tendon or ligament tissue having sufficient strength. More specifically, artificial tendon or ligament tissue having sufficient strength is provided by embedding collagen-secreting cells in a gel having strength capable of resisting a tensile load and by culturing the cells while applying a tensile load to the gel to produce artificial tendon or ligament tissue. Cells that steadily express the Mkx gene can be used as the collagen-secreting cells. A fibrin gel containing aprotinin can be used as the gel.

Abstract: Described herein are immunoresponsive cells which are useful for their preventive and therapeutic potential against autoimmune diseases and rejections of solid organ transplants.

Abstract: An isolated rat liver cancer stem cell line which is named as TW-1 is provided. A method for drug screening by using the isolated rat liver cancer stem cell line is also provided.

Abstract: The present disclosure provides a combination of antisense RNA sequences and use thereof in the production of tilapia with degenerated sexual organs, belonging to the technical field of molecular biology and reproductive biology, the combination of antisense RNA sequences includes antisense RNA of steroidogenic factors SF1-1 and SF1-2; the nucleotide sequences of Anti-SF1-1-I, Anti-SF1-1-II, Anti-SF1-2-I and Anti-SF1-2-II are set forth in SEQ ID NO:1-SEQ ID NO:4 respectively. The method of the present disclosure introduces antisense RNA fragments into the eggs through the fertilization hole to realize effective and accurate targeted intervention for regulating the gene expression, and the method has the advantages of simple operation, minimal egg damage, high success rate, stable phenotype after breeding, and excellent application prospects.

Abstract: The present invention relates to a method for isolating Glu-plasminogen, said method comprising the anion exchange chromatography of blood plasma or a plasma fraction comprising Glu-plasminogen. Furthermore, the present invention relates to Glu-plasminogen obtainable from the method of the present invention and its use in a method for treating a patient suffering from or being at risk of developing a disorder selected from the group consisting of organ failure, a thrombotic event, arterial obstructive disease, microcirculation, disseminated intravascular coagulation (DIC), and a combination of two or more thereof.